Understanding of neurodegenerative processes
.
Alzheimer's Donation
Donate Online Now
.
The same research team who discovered an age-related neurological disorder will now receive nearly 21.8 million dollars from the National Institutes of Health (NIH) to develop new treatments for it. The funding establishes the NeuroTherapeutics Research Institute at the University of California, Davis, which is dedicated to finding effective interventions that reduce or eliminate the debilitating balance problems, tremors and dementia associated with older adults who have FXTAS, or fragile X-associated tremor/ataxia syndrome. The five-year grant is the largest funding award in history to focus on this or any other fragile X-related disorder.
Led by molecular geneticist Paul Hagerman, the institute is one of nine interdisciplinary research consortia announced today by the NIH Roadmap for Medical Research. The roadmap's goal is to integrate different disciplines to address health challenges that have been resistant to traditional research approaches. Funding the consortia represents a fundamental change in both the culture within which biomedical and behavioral research is conducted and the culture within the NIH, where research projects are normally managed by an individual institute or center.
"Dr. Hagerman and his colleagues have put together an impressive team of scientists with expertise in genetics, neurophysiology, neuroimaging and therapeutics development to identify new treatment options for neurogenetic disorders such as FXTAS," said Larry Tabak, director of the National Institute of Dental and Craniofacial Research and co-chair of the working group that identified the science to be funded. "The environment for interdisciplinary research at UC Davis is viewed as highly conducive for novel research of this type."
"Today, hope has found a home here at UC Davis -- for FXTAS patients and for many more, including the growing millions of Americans who suffer from Alzheimer's, Parkinson's and other neurodegenerative disorders," said Claire Pomeroy, vice chancellor of Human Health Sciences and dean of the School of Medicine at UC Davis. "This new institute is a perfect fit for the collaborative culture we have fostered throughout UC Davis Health System. Through it, we will continue to break down silos among disciplines, specialties and departments in order to speed the progress of scientific discoveries."
Discovered in 2001 by Paul Hagerman and Randi Hagerman, FXTAS (pronounced "FAX-tass") affects carriers of a small mutation - also called a premutation - in the same gene that causes fragile X syndrome. The genetic mutation is the most common cause of inherited mental impairment and the leading single-gene cause of autism in children. Prior to its discovery, FXTAS was often misdiagnosed as Alzheimer's disease, Parkinson's disease or the more rare Charcot-Marie-Tooth syndrome. In addition to finding treatments that specifically target FXTAS, institute researchers will improve understanding of all age-related neurodegenerative processes.
Vitamin B from LycoRed to be added to fizzy drinks
LycoRed has said a range of its vitamin B complex will be launched in a line of carbonated drinks - a task made challenging by solubility issues.
posted YVN
.
Alzheimer's Donation
Donate Online Now
.
The same research team who discovered an age-related neurological disorder will now receive nearly 21.8 million dollars from the National Institutes of Health (NIH) to develop new treatments for it. The funding establishes the NeuroTherapeutics Research Institute at the University of California, Davis, which is dedicated to finding effective interventions that reduce or eliminate the debilitating balance problems, tremors and dementia associated with older adults who have FXTAS, or fragile X-associated tremor/ataxia syndrome. The five-year grant is the largest funding award in history to focus on this or any other fragile X-related disorder.
Led by molecular geneticist Paul Hagerman, the institute is one of nine interdisciplinary research consortia announced today by the NIH Roadmap for Medical Research. The roadmap's goal is to integrate different disciplines to address health challenges that have been resistant to traditional research approaches. Funding the consortia represents a fundamental change in both the culture within which biomedical and behavioral research is conducted and the culture within the NIH, where research projects are normally managed by an individual institute or center.
"Dr. Hagerman and his colleagues have put together an impressive team of scientists with expertise in genetics, neurophysiology, neuroimaging and therapeutics development to identify new treatment options for neurogenetic disorders such as FXTAS," said Larry Tabak, director of the National Institute of Dental and Craniofacial Research and co-chair of the working group that identified the science to be funded. "The environment for interdisciplinary research at UC Davis is viewed as highly conducive for novel research of this type."
"Today, hope has found a home here at UC Davis -- for FXTAS patients and for many more, including the growing millions of Americans who suffer from Alzheimer's, Parkinson's and other neurodegenerative disorders," said Claire Pomeroy, vice chancellor of Human Health Sciences and dean of the School of Medicine at UC Davis. "This new institute is a perfect fit for the collaborative culture we have fostered throughout UC Davis Health System. Through it, we will continue to break down silos among disciplines, specialties and departments in order to speed the progress of scientific discoveries."
Discovered in 2001 by Paul Hagerman and Randi Hagerman, FXTAS (pronounced "FAX-tass") affects carriers of a small mutation - also called a premutation - in the same gene that causes fragile X syndrome. The genetic mutation is the most common cause of inherited mental impairment and the leading single-gene cause of autism in children. Prior to its discovery, FXTAS was often misdiagnosed as Alzheimer's disease, Parkinson's disease or the more rare Charcot-Marie-Tooth syndrome. In addition to finding treatments that specifically target FXTAS, institute researchers will improve understanding of all age-related neurodegenerative processes.
LycoRed has said a range of its vitamin B complex will be launched in a line of carbonated drinks - a task made challenging by solubility issues.
posted by Valery Yermalitsky at
7:20 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home